Abstract submitters may participate in the application process for the following awards:
The winners of the Top 10 DOP awards are:
DOP05: Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients - Elisa Melón-Ardanaz, Barcelona, Spain
DOP16: Anti-integrin ⍺vβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes – Alexandra Livanos, New York, United States
DOP22: Antibiotic Use as a Risk Factor for Inflammatory Bowel Disease Across the Ages: A Population-Based Cohort Study – Adam Faye, New York, United States
DOP33: Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn’s Disease – Gianluca Matteoli, Leuven, Belgium
DOP53: Community types of the human gut virome are associated with endoscopic outcome in UC patients – Daan Jansen, Leuven, Belgium
DOP60: Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India – Rupa Banerjee, Hyderabad, India
DOP68: Autophagy induction in the intestinal epithelium protects against inflammation-induced barrier loss in vivo – Kushal Saha, Hershey, United States
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis – Ololade Lawal, Dublin, Ireland
DOP85: Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial – Julien Schulberg, Fitzroy, Australia
The winners are:
OP02: Nicolas Pierre
OP37: Maria Chaparro
The Clinical Research Committee of ECCO (ClinCom) wants to stimulate the development of high-quality Investigator-Initiated Studies (IIS) in IBD and to improve the quality of IBD clinical studies in Europe through education. In 2023, awards will be given to the 2 best congress abstracts reporting on clinical studies set up by investigators (preferably multi-centre) submitted for the ECCO Congress. Note: Studies conducted by industry will not be eligible for this award.
Responsible Committee: Clinical Research Committee of ECCO (ClinCom)
Prize: Free registration for the ECCO Congress 2024
Number of awards: 2
Who can apply: ECCO Members reporting on clinical studies set up by investigators in their abstracts. Note: ECCO Membership fee 2023 must be paid up until the abstract submission deadline.
How to apply:
The winners are:
OP01: Sare Verstockt
OP18: Mads Damsgaard
OP29: Sun-Ho Lee
DOP05: Elisa Melón-Ardanaz
DOP57: Heidi Soegaard
The Young ECCO (Y-ECCO) encourages Y-ECCO Members to submit their abstract and share their research with the ECCO Community. Awards will be given to the 5 best-ranked abstracts along with a free congress registration for the following year.
Responsible Committee: Young-ECCO (Y-ECCO)
Prize: Free registration for the ECCO Congress 2024
Number of awards: 5
Who can apply: Y-ECCO Members (below 35 years of age or still in training). Note: ECCO Membership fee 2023 must be paid up until the abstract submission deadline.
How to apply: